Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19990743 | 0.73 | MAPT (0.42) | MAPTFUCA1ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL8044343 | 0.72 | CD274 (0.50) | MAPTFUCA1KDM4EL3MBTL1GBA1 | |
| SCHEMBL20745515 | 0.72 | CD274 (0.50) | MAPTFUCA1KDM4EL3MBTL1GBA1 | |
| SCHEMBL5067829 | 0.72 | CD274 (0.50) | MAPTFUCA1KDM4EL3MBTL1GBA1 | |
| SCHEMBL6545054 | 0.72 | CD274 (0.50) | MAPTFUCA1KDM4EL3MBTL1GBA1 | |
| SCHEMBL9218563 | 0.72 | CD274 (0.50) | MAPTFUCA1KDM4EL3MBTL1GBA1 | |
| SCHEMBL28513094 | 0.71 | MAPT (0.73) | MAPTFUCA1ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL28498890 | 0.71 | MAPT (0.73) | MAPTFUCA1ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL8936135 | 0.71 | MAPT (0.73) | MAPTFUCA1ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL4130506 | 0.71 | MAPT (0.73) | MAPTFUCA1ALDH1A1KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3698796-A1 | PHARMACEUTICAL COMBINATION OF A TRICYCLIC BETA-LACTAMASE INHIBITOR WITH SPECIFIC BETA-LACTAM ANTIBIOTICS | Novartis AG (CH) | 2020-08-26 | — | — | EP | disclosed |